The 2020-21 Annual Report details how Peter Mac continued to provide the best in cancer care, throughout an extraordinary year.

Despite the disruption and change caused by the COVID-19 pandemic, 2021 was a year of innovation and adaptation. Throughout the year Peter Mac made significant advances in the first year of implementing its Strategic Directions 2020-2025.

Detail on the many achievements and services provided to the community during 2020-2021 have been outlined in the Annual Report, which was released at Peter Mac’s Annual General Meeting held on 6 December 2021.

Snapshot of our year:

Our patient care
  • 38,776 patients
  • 41,923 inpatient separations
  • 240,073 specialist appointments
  • 25,142 telehealth appointments
  • 3,201 elective surgery patients
  • 2,758 nuclear medicine scans
  • 9,381 PET scans
  • 220,274 pathology requests.
Our research
  • 40 research laboratories, including 3 translational research labs
  • 501 active clinical trials
  • $128.3m in research income
  • 939 publications, including 182 in high-impact journals
  • The new Strategic Plan for 2020 – 2025 articulates the ambitions of the Research division for delivering large scale, fundamental pre-clinical and clinical cancer research integrated with clinical care and education.
Our people
  • 3,300 employees
  • 750 researchers, including students
  • 170 registered volunteers
  • 155 higher-degree students
  • $25.5 million in philanthropic funding through donations to the Peter MacCallum Cancer Foundation, supporting life-saving cancer research.
Our financial performance
  • For the year ending 30 June 2021, excluding capital and specific items, Peter Mac recorded an operating surplus of $220,000.

Peter Mac extends heartfelt thanks to the community we are proud to serve.

Read the 2020-21 Peter MacCallum Cancer Centre Annual Report

View the